Cargando…

Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data

BACKGROUND: Blood tests can support the diagnostic process in patients with cancer but how often they are used is unclear. AIM: To explore use of common blood tests before cancer diagnosis in primary care. DESIGN AND SETTING: English National Cancer Diagnosis Audit data on 39 752 patients with cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Cranfield, Ben M, Koo, Minjoung Monica, Abel, Gary A, Swann, Ruth, McPhail, Sean, Rubin, Greg P, Lyratzopoulos, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal College of General Practitioners 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9591015/
https://www.ncbi.nlm.nih.gov/pubmed/36253112
http://dx.doi.org/10.3399/BJGP.2022.0265
_version_ 1784814617995771904
author Cranfield, Ben M
Koo, Minjoung Monica
Abel, Gary A
Swann, Ruth
McPhail, Sean
Rubin, Greg P
Lyratzopoulos, Georgios
author_facet Cranfield, Ben M
Koo, Minjoung Monica
Abel, Gary A
Swann, Ruth
McPhail, Sean
Rubin, Greg P
Lyratzopoulos, Georgios
author_sort Cranfield, Ben M
collection PubMed
description BACKGROUND: Blood tests can support the diagnostic process in patients with cancer but how often they are used is unclear. AIM: To explore use of common blood tests before cancer diagnosis in primary care. DESIGN AND SETTING: English National Cancer Diagnosis Audit data on 39 752 patients with cancer diagnosed in 2018. METHOD: Common blood test use (full blood count [FBC], urea and electrolytes [U&E], and liver function tests [LFTs]), variation by patient and symptom group, and associations with the primary care interval and the diagnostic interval were assessed. RESULTS: At least one common blood test was used in 41% (n = 16 427/39 752) of patients subsequently diagnosed with cancer. Among tested patients, (n = 16 427), FBC was used in 95% (n = 15 540), U&E in 89% (n = 14 555), and LFTs in 76% (n = 12 414). Blood testing was less common in females (adjusted odds ratio versus males: 0.92, 95% confidence interval [CI] = 0.87 to 0.98) and Black and minority ethnic patients (0.89, 95% CI = 0.82 to 0.97 versus White), and more common in older patients (1.12, 95% CI = 1.06 to 1.18 for ≥70 years versus 50–69 years). Test use varied greatly by cancer site (melanoma 2% [ n = 55/2297]; leukaemia 84% [ n = 552/661]). Fewer patients presenting with alarm symptoms alone were tested (24% [ n = 3341/13 778]) than those with non-alarm symptoms alone (50% [ n = 8223/16 487]). Median primary care interval and diagnostic interval were longer in tested than non-tested patients (primary care interval: 10 versus 0 days; diagnostic interval: 49 versus 32 days, respectively, P<0.001 for both), including among tested patients with alarm symptoms (primary care interval: 4 versus 0 days; diagnostic interval: 41 versus 22 days). CONCLUSION: Two-fifths of patients subsequently diagnosed with cancer have primary care blood tests as part of their diagnostic process. Given variable test use, research is needed on the clinical context in which blood tests are ordered.
format Online
Article
Text
id pubmed-9591015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Royal College of General Practitioners
record_format MEDLINE/PubMed
spelling pubmed-95910152022-10-31 Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data Cranfield, Ben M Koo, Minjoung Monica Abel, Gary A Swann, Ruth McPhail, Sean Rubin, Greg P Lyratzopoulos, Georgios Br J Gen Pract Research BACKGROUND: Blood tests can support the diagnostic process in patients with cancer but how often they are used is unclear. AIM: To explore use of common blood tests before cancer diagnosis in primary care. DESIGN AND SETTING: English National Cancer Diagnosis Audit data on 39 752 patients with cancer diagnosed in 2018. METHOD: Common blood test use (full blood count [FBC], urea and electrolytes [U&E], and liver function tests [LFTs]), variation by patient and symptom group, and associations with the primary care interval and the diagnostic interval were assessed. RESULTS: At least one common blood test was used in 41% (n = 16 427/39 752) of patients subsequently diagnosed with cancer. Among tested patients, (n = 16 427), FBC was used in 95% (n = 15 540), U&E in 89% (n = 14 555), and LFTs in 76% (n = 12 414). Blood testing was less common in females (adjusted odds ratio versus males: 0.92, 95% confidence interval [CI] = 0.87 to 0.98) and Black and minority ethnic patients (0.89, 95% CI = 0.82 to 0.97 versus White), and more common in older patients (1.12, 95% CI = 1.06 to 1.18 for ≥70 years versus 50–69 years). Test use varied greatly by cancer site (melanoma 2% [ n = 55/2297]; leukaemia 84% [ n = 552/661]). Fewer patients presenting with alarm symptoms alone were tested (24% [ n = 3341/13 778]) than those with non-alarm symptoms alone (50% [ n = 8223/16 487]). Median primary care interval and diagnostic interval were longer in tested than non-tested patients (primary care interval: 10 versus 0 days; diagnostic interval: 49 versus 32 days, respectively, P<0.001 for both), including among tested patients with alarm symptoms (primary care interval: 4 versus 0 days; diagnostic interval: 41 versus 22 days). CONCLUSION: Two-fifths of patients subsequently diagnosed with cancer have primary care blood tests as part of their diagnostic process. Given variable test use, research is needed on the clinical context in which blood tests are ordered. Royal College of General Practitioners 2022-10-18 /pmc/articles/PMC9591015/ /pubmed/36253112 http://dx.doi.org/10.3399/BJGP.2022.0265 Text en © The Authors https://creativecommons.org/licenses/by/4.0/This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licences/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Research
Cranfield, Ben M
Koo, Minjoung Monica
Abel, Gary A
Swann, Ruth
McPhail, Sean
Rubin, Greg P
Lyratzopoulos, Georgios
Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data
title Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data
title_full Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data
title_fullStr Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data
title_full_unstemmed Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data
title_short Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data
title_sort primary care blood tests before cancer diagnosis: national cancer diagnosis audit data
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9591015/
https://www.ncbi.nlm.nih.gov/pubmed/36253112
http://dx.doi.org/10.3399/BJGP.2022.0265
work_keys_str_mv AT cranfieldbenm primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata
AT koominjoungmonica primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata
AT abelgarya primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata
AT swannruth primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata
AT mcphailsean primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata
AT rubingregp primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata
AT lyratzopoulosgeorgios primarycarebloodtestsbeforecancerdiagnosisnationalcancerdiagnosisauditdata